The US Food and Drug Administration has approved Fulphila (pegfilgrastim-jmbd), a biosimilar to Amgen’s (Nasdaq: AMGN) Neulasta(pegfilgrastim).
Fulphila has been approved to reduce the duration of febrile neutropenia (fever or other signs of infection with a low count of neutrophils, a type of white blood cells) in patients treated with chemotherapy in certain types of cancer.
The biosimilar was co-developed by Netherlands-incorporated Mylan (Nasdaq: MYL) and India’s Biocon BSE: 532523), with news of the long awaited approval sending Mylan’s share up 5.2% to $40.50 in after-hours trading on Monday, while Amgen fell 1.7% to $182.30.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze